Why is "Danavorexton" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-06-04 16:22:19
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Danavorexton entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-06-04 and was most recently seen on 2026-06-04.
Wikipedia Overview
Danavorexton is a selective orexin 2 receptor agonist. It is a small-molecule compound and is administered intravenously. The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. It is related to another orexin receptor agonist, firazorexton (TAK-994), the development of which was discontinued for safety reasons in October 2021.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients - PNAS
-
Takeda stops phase 2 post-anesthesia recovery trial over slow enrollment - Fierce Biotech
-
Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1 - The New England Journal of Medicine
-
Fierce Pharma Asia—AZ exec under investigation in China; GSK's lupus deal; Takeda's orexin hiccup - Fierce Pharma
-
TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models - Nature
-
Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers - Wiley Online Library
-
Takeda drops AstraZeneca-partnered neurological program after phase 2 failure - Fierce Biotech
-
Fierce Pharma Asia—Takeda pipeline cuts; Innovent, Lilly win against semaglutide; Roche's bispecific deal - Fierce Pharma
-
Takeda shoots down bispecifics bagged in Maverick buyout amid pipeline clearout - Fierce Biotech
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.